^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
12/06/2022
Excerpt:
Pancreatic Adenocarcinoma...Other Recommended Regimens...Dabrafenib + trametinib (if BRAF V600E mutation positive)...
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Non Small Cell Lung Cancer)
New
Excerpt:
TAFINLAR is indicated, in combination with trametinib, for...the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.